25 Aug 2020 Governance

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.

Angela was responsible for driving through the merger with Leuka in November 2019, and is now leaving the charity in a strong position to build on the remarkable transformation she engineered.

She has been a valued Co CEO of the merged charity and a visionary sole CEO of the original charity. We thank her for her outstanding work on our behalf and wish her the very best in the future.

Related posts

Nurse who made throwaway comment before blood cancer diagnosis welcomes new research boost into ‘Natural Killer’ cells

29 February 2024

Nurse who made throwaway comment before blood cancer diagnosis welcomes new research boost into ‘Natural Killer’ cells

A former nurse, midwife, health visitor and NHS manager is welcoming new research into her particular blood cancer, after not recognising her mystery symptoms were leukaemia.  Kay Cutting, from Seaham…

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

8 September 2022

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement: “We are extremely saddened to hear the news of the death of…

Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia

30 January 2024

Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia

Leukaemia UK is pleased to announce Dr Simon Ridley as the new Director of Research and Advocacy and Dr Georgia Papacleovoulou as the organisation’s first ever Head of Policy and…

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.